Procter & Gamble To Cut 7,000 Jobs Due To Economic Uncertainty
Consumer goods company Procter & Gamble (PG) has announced that it is cutting 7,000 non-manufacturing jobs over the next two years as it grapples with economic uncertainty.The maker of Gillette razor blades and Tide laundry detergent said the job cuts amount to 15% of its non-manufacturing workforce.Executives with Procter & Gamble said they also plan to exit certain brands and markets as part of a new restructuring program.Additional details on the restructuring plan will be unveiled on the company’s fiscal year-end earnings call in July.Procter & Gamble exited the food business more than a decade ago to focus on core brands such as Pampers diapers and Old Spice deodorant. The latest job cuts, and restructuring plan, come amid a prolonged slump for Procter & Gamble coming out of the Covid-19 pandemic. The Cincinnati, Ohio-based company cut its full-year earnings guidance in April of this year, citing a tough macroeconomic and geopolitical environment. Management have said that the company will likely raise some of its prices this summer in response to current market challenges.Procter & Gamble’s net profit has risen only 12% over the past three years, and its share price has gained less than 20% over the same time period.The company’s stock is flat so far in 2025 (down 0.02%) and trading at $165.95 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


